RecruitingOvarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
Eligible age
18+ yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Sponsor: Nurix Therapeutics, Inc.
Where it's recruiting
California
Duarte · Los Angeles · San Francisco
Colorado
Aurora
Illinois
Chicago
North Carolina
Chapel Hill
Oklahoma
Oklahoma City
Texas
Houston
Virginia
Charlottesville
Washington
Seattle
Source: ClinicalTrials.gov · NCT05107674 · last updated 2025-09-09